The fight against HIV stands as one of humanity’s greatest achievements. Yet, decades of progress now face a critical threat. On June 5, 1981, the Centers for Disease Control and Prevention (CDC) reported five cases of a deadly pneumonia in young men in Los Angeles—the first recorded chapter of what would become the deadliest infectious disease epidemic since the 1918 flu. The virus, eventually named human immunodeficiency virus (HIV), would claim an estimated 44 million lives worldwide, reshaping medicine, politics, and culture.
From Death Sentence to Manageable Condition
For fifteen years, an HIV diagnosis was a virtual death sentence. The virus mutated rapidly, making treatment elusive. Early victims faced stigma and isolation. It took until 1985 for President Reagan to publicly acknowledge AIDS, by which point 6,000 Americans had already died. By 1993, HIV was the leading cause of death among young adults in the US, peaking in 1995 with 50,628 AIDS-related deaths. Globally, infections peaked in 1996 at 3.4 million, and sub-Saharan Africa was devastated with one in five adults infected. By 2000, AIDS was the leading cause of death on the African continent.
Yet, this grim trajectory didn’t define the story’s end. Activist pressure, scientific breakthroughs, and bipartisan political action reversed the course. In 1996, combination antiretroviral therapy (HAART) emerged, dramatically reducing AIDS-related deaths and hospitalizations by 60-80%. Patients who were days from death recovered, an effect doctors termed the “Lazarus effect.”
Global Inequality and the PEPFAR Breakthrough
Early antiretrovirals cost $10,000 to $15,000 per year, making them accessible in the US but unattainable for millions in impoverished sub-Saharan Africa. By 2003, only 50,000 Africans had access to these lifesaving drugs, while 30 million were infected. Roughly 12 million died between 1997 and 2006 due to cost and supply bottlenecks.
In 2003, President George W. Bush launched the President’s Emergency Plan for AIDS Relief (PEPFAR), pledging $15 billion over five years to fight AIDS abroad. The program expanded rapidly, reaching 400,000 people in 2005 and 2 million by 2008. As of today, PEPFAR has invested over $120 billion and saved an estimated 26 million lives. The cost of treatment in low-income countries has plummeted from $1,200 per year in 2003 to $58 in 2023.
A Near-Eradicable Disease… at Risk
Today, someone diagnosed with HIV who receives treatment can expect a near-normal lifespan. Prevention tools, like PrEP (a daily pill reducing HIV risk by up to 99%) and the new twice-yearly injection lenacapavir (with zero infections in clinical trials), have further reduced transmission. Undetectable equals Untransmittable (U=U)—meaning virally suppressed individuals cannot transmit the virus sexually—normalizes the disease and limits its spread. Community health workers in Kenya and Uganda have cut new infections by 70% through immediate treatment programs.
However, 630,000 people still die from AIDS annually. 9.2 million who need treatment lack access, disproportionately affecting marginalized populations: sex workers, men who have sex with men, drug users, and transgender people now account for over 55% of new infections.
The Looming Crisis: Funding Cuts and Political Backlash
Two-thirds of people living with HIV reside in sub-Saharan Africa, where external funding sustains 80% of prevention programs. Now, PEPFAR’s reauthorization lapsed in March 2025, freezing programs worldwide. USAID contract cancellations threaten to gut its infrastructure. UNAIDS estimates that without sustained funding, 6 million additional infections and 4 million deaths could occur by 2029. Even the US faces cuts to the AIDS Drug Assistance Program, threatening coverage for a quarter of Americans living with HIV.
We have the tools to end this epidemic: effective treatments, prevention methods, and even vaccine research. The challenge is no longer scientific but political and financial. The same forces that drove PEPFAR’s success two decades ago must be mobilized again. The story of HIV is a testament to human potential when action is prioritized. Will we make that decision once more?
